SCIENTIFIC ARTICLE

Intravenous lidocaine for post-mastectomy pain treatment: randomized, blind, placebo controlled clinical trial

Tania Cursino de Menezes Couceiro¹,∗, Luciana Cavalcanti Lima²,⁎, Léa Menezes Couceiro Burle³, Marcelo Moraes Valença³

¹ Instituto de Medicina Integral Professor Fernando Figueira (IMIP), Recife, PE, Brazil
² Faculdade Pernambucana de Saúde (FBS), Recife, PE, Brazil
³ Department of Neurology and Neurosurgery, Universidade Federal de Pernambuco, Recife, PE, Brazil

Received 28 April 2014; accepted 19 May 2014
Available online 30 March 2015

Abstract

Background and objective: Postoperative pain treatment in mastectomy remains a major challenge despite the multimodal approach. The aim of this study was to investigate the analgesic effect of intravenous lidocaine in patients undergoing mastectomy, as well as the postoperative consumption of opioids.

Methods: After approval by the Human Research Ethics Committee of the Instituto de Medicina Integral Prof. Fernando Figueira in Recife, Pernambuco, a randomized, blind, controlled trial was conducted with intravenous lidocaine at a dose of 3 mg/kg infused over 1 h in 45 women undergoing mastectomy under general anesthesia. One patient from placebo group was.

Results: Groups were similar in age, body mass index, type of surgery, and postoperative need for opioids. Two of 22 patients in lidocaine group and three of 22 patients in placebo group requested opioid (p = 0.50). Pain on awakening was identified in 4/22 of lidocaine group and 5/22 of placebo group (p = 0.50); in the post-anesthetic recovery room in 14/22 and 12/22 (p = 0.37) of lidocaine and placebo groups, respectively. Pain evaluation 24 h after surgery showed that 2/22 and 3/22 patients (p = 0.50) of lidocaine and placebo groups, respectively, complained of pain.

Conclusion: Intravenous lidocaine at a dose of 3 mg/kg administered over a period of an hour during mastectomy did not promote additional analgesia compared to placebo in the first 24 h, and has not decreased opioid consumption. However, a beneficial effect of intravenous lidocaine in selected and/or other therapeutic regimens patients cannot be ruled out.

© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.

∗ Corresponding author.
E-mails: taniacouceiro@yahoo.com.br, taniacursinomcouceiro@gmail.com (T.C.d.M. Couceiro).

http://dx.doi.org/10.1016/j.bjane.2014.05.017
0104-0014/© 2014 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. All rights reserved.
Introduction

Postoperative pain remains inadequately treated despite its predictability and progress of various analgesic techniques and drugs available for its control. Some authors report that, regardless of the type of surgical procedure, postoperative pain is present and with varying intensity. The incidence of postoperative pain in breast cancer is low when treated properly, however, it can result in cardiovascular and respiratory complications, as well as persistent postoperative pain. Therefore, adequate pain control is of paramount importance in clinical practice.

In this context, the multimodal approach to postoperative pain should be considered, given the analgesic results obtained with each particular drug and the lower incidence of adverse effects.

In order to provide postoperative analgesia, intravenous lidocaine has been used intra- and post-operatively as part of multimodal approach, with proven analgesic effect in postoperative abdominal and pelvic surgery, such as colectomy and prostatectomy, respectively.

In addition to the analgesic action, local anesthetics have anti-inflammatory action, justifying the use of intravenous lidocaine to modulate the inflammatory response resulting from postoperative pain. Other benefits are the reduced need for postoperative opioids, reduced complications such as nausea and vomiting, and reduced pain intensity in the first 24h.

Meta-analyses show conflicting results regarding the analgesic effect of lidocaine on postoperative pain, highlighting the need to specify the real value of intravenous lidocaine for postoperative pain relief in patients undergoing mastectomy. The objective of this study was to investigate the analgesic effect of intravenous lidocaine in the first 24h in women undergoing mastectomy, as well as to assess the consumption of opioids postoperatively.

Methods

After approval by the Human Research Ethics Committee of the Integrative Medicine Institute Prof. Fernando Figueira (IMIP), under number 2026 CAAE 0202009917210, and obtaining written informed consent from participants, a randomized, placebo controlled, blind clinical trial was performed from July 2011 to August 2012, at the IMIP, Recife, Pernambuco, Brazil.

The study included women aged between 18 and 75 years who underwent mastectomy for breast cancer treatment. Exclusion criteria were patients with relative or absolute contraindication to the use of lidocaine (allergy to local anesthetics, changes in atrioventricular conduction, uncontrolled epilepsy, porphyria, and malignant hyperthermia), those receiving antidepressants and/or anticonvulsants, with cardiac arrhythmia and any type of rheumatic disease, distant metastasis or in contralateral breast, patients who...
do not understand the numerical scale (NS) of pain assessment and/or have used opioids in the past 24h.

Data were collected using a standardized questionnaire to characterize the sample. Data included age, body mass index (BMI), type of surgery, adjuvant treatment, and pain history, such as headache and surgery breast pain. The variables studied were presence and intensity of pain 24h after surgery at three different time points (M1 upon awakening from anesthesia, M2 = 1h after admission to the post-anesthesia care unit (PACU), and M3 = 24h after the surgical procedure) and the need for postoperative opioids. Pain was assessed at rest, using a NS pain from 0 to 10 (0 = no pain and 10 = worst possible pain). For analysis, pain severity was categorized as absent (0), mild (1–3), moderate (4–7), severe (7–9), and very severe (10).

Patients were randomly allocated into two groups (lidocaine or placebo) on a 1:1 ratio by drawing blocks of four patients, as in the event of suspension or discontinuation of study, the number of patients would remain similar in both groups. To ensure that the study was blind, the lidocaine and placebo ampoules were prepared in similar vials and numbered sequentially. All patients underwent general anesthesia with fentanyl (5 μg kg⁻¹), propofol (1.0 mg kg⁻¹), and rocuronium (0.3 mg kg⁻¹) and maintained with 1.5% sevoflurane in 50% fraction of inspired oxygen. Bolus dose of lidocaine was not administered and, after incision, the 1h infusion of saline solution (100 mL) containing the total dose of lidocaine (3 mg kg⁻¹) or placebo was started.

All patients received intravenous dipyrone (2 g) and ketoprofen (100 mg) during surgery as prophylaxis of postoperative pain. The chest wall was infiltrated with a solution containing 0.025% bupivacaine and epinephrine 1:400,000, according to the Mastology Service conduct. For postoperative analgesia 1g dipyrone was prescribed every 6h. In case of pain, codeine (30 mg) associated with paracetamol (200 mg) was prescribed to be administered according to patients’ request.

The sample size calculation was based on the assumption of a 5% alpha-error, 10% beta-error, and 90% power and considering that lidocaine group had a 70% reduction in opioid consumption, while the placebo group would have a 30% reduction. A loss of 10% was presumed, resulting in 44 subjects divided into two groups of 22 patients each.

For data analysis, EPI-INFOLSTM software version 3.5.1 for WindowsTM was used. Data were presented as absolute and relative frequency distribution and presented in tables. Numerical variables were represented as measures of central tendency (mean) and dispersion (standard deviation and range). Chi-square test with Yates’ correction application and Fisher’s exact test were used to verify the existence of an association between categorical variables. A p-value < 0.05 was considered significant.

Results

Forty-four patients who underwent mastectomy were evaluated, 22 from lidocaine group and 22 from placebo group (Fig. 1, flowchart). One patient from placebo group was excluded because, although she has shown to understand how to use the proposed rating scale of pain (NS) and therefore have been included in the study, she could not evaluate the pain using the NS postoperatively. The groups were similar in age, body mass index, adjuvant chemotherapy treatment before mastectomy, and history of pain (Table 1). Regarding the type of surgery, two-thirds of patients in both groups underwent Madden’s mastectomy and the other one-third underwent mastectomy with sentinel lymph node removal (Table 1).

There was no difference between groups regarding postoperative pain at rest in any of the time points assessed: upon awakening from anesthesia (M1), 1 h after PACU admission (M2), and 24 h after the surgical procedure (M3) (Table 2).

Opioid consumption in the first 24h after surgery was similar in the lidocaine and placebo groups (Table 2).

Discussion

This study demonstrated that intravenous administration of lidocaine during surgery at a dose of 3 mg kg⁻¹ in 1h was not superior to placebo for postoperative analgesia in patients undergoing mastectomy.

Other authors reported benefit with the use of intravenous lidocaine for postoperative pain relief. The authors found improved analgesia in patients undergoing laparoscopic colectomy when using an initial dose of 1.5 mg kg⁻¹ followed by continuous infusion of 2.0 mg kg⁻¹ h⁻¹, which lasted for 24h postoperatively.

De Oliveira et al. evaluating pain in women undergoing, ambulatory laparoscopic surgery who received lidocaine (1.5 mg kg⁻¹) 20 min prior to surgical incision, followed by an infusion of 2 mg kg⁻¹ h⁻¹ up to the end of surgical procedure, observe pain relief in the lidocaine group.

The lidocaine benefit evidenced by these authors may be related to the different infusion regimens used. The infusion...
of lidocaine for 24 h postoperatively may have resulted in suppression of central sensitization\textsuperscript{15} and thus contributed to obtain good analgesic effect in comparison with our study. The use of bolus before surgery may lead us to think that the administration of lidocaine before surgical incision can promote better postoperative pain results by reducing the release of inflammatory substances.

Regarding the dose, in a recent study\textsuperscript{16} using intravenous lidocaine in patients who underwent mastectomy, the authors evaluated 36 patients divided into two groups, with 19 women in the placebo group and 17 in the lidocaine group. Lidocaine was administered at a dose of 1.5 mg kg\textsuperscript{-1} before surgical incision, followed by the same dose every hour, which lasted up to 60 min after closing the surgical incision. The perioperative conduct for postoperative pain management was the use of ketorolac at a single dose of 30 mg. The authors found that lidocaine was able to provide superior analgesia to placebo only in the fourth hour after surgery. These authors\textsuperscript{16} found a decrease in the central hyperalgesia and a decreased incidence and severity of persistent postoperative pain in the lidocaine group.

In our study, the absence of additional analgesic effect in the early postoperative period (first 4 h after surgery) in the lidocaine group may have been masked by the efficiency of the preconized postoperative pain prophylaxis, as we the administration of ketoprofen (100 mg) and dipyridine (2 g) followed by dipyridine (1 g) every 6 h for 24 h was systematized. Associated with these drugs, infiltration of the chest wall ipsilateral to the mastectomy with local anesthetic and vasoconstrictor was performed in all patients.

Currently, there is no consensus about the best lidocaine administration method. Several infusion regimens have been used: exclusively during surgery,\textsuperscript{8} intraoperatively and continued for 1 h\textsuperscript{10} or 24 h\textsuperscript{10}, and even as patient-controlled analgesia.\textsuperscript{17} However, in our study the choice of lidocaine administration for a period of 1 h without using an initial dose (bolus) was based on a report of another study by this investigator,\textsuperscript{18} which showed benefit when using intravenous lidocaine for a short period of time, and because the surgical procedure in the institution usually has an average duration of 1 h.

The choice of the 3 mg kg\textsuperscript{-1} dose was based on the analgesics results of therapeutic doses used in clinical practice (2–5 mg mL\textsuperscript{-1}), which achieved serum levels of 2 μg mL\textsuperscript{-1}. Because the mild adverse effects begin with serum levels above 3 μg mL\textsuperscript{-1}, this dose results in a safety pharmacology window for the use of intravenous lidocaine.\textsuperscript{19,20}

Therefore, studies that stipulate the beginning of IL infusion in relation to the surgical incision time, duration of infusion in the postoperative period, and the total dose of intravenous lidocaine to be administered are required to define its actual role in postoperative analgesia in women undergoing mastectomy.

However, the non-observation of analgesic advantages in patients undergoing mastectomy may be more related to the type of pain resulting from surgical procedure than

---

### Table 1: Sample characterization according to groups.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Lidocaine</th>
<th>Placebo</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)\textsuperscript{a}</td>
<td>52.4 ± 12.4</td>
<td>47.0 ± 11.0</td>
<td>0.10\textsuperscript{b}</td>
</tr>
<tr>
<td>BMI\textsuperscript{a}</td>
<td>28.1 ± 8.1</td>
<td>28.2 ± 3.9</td>
<td>0.89\textsuperscript{b}</td>
</tr>
<tr>
<td>Prior QT</td>
<td>11/22 (50%)</td>
<td>10/22 (45.4%)</td>
<td>0.38\textsuperscript{c}</td>
</tr>
<tr>
<td>Headache</td>
<td>6/22 (30%)</td>
<td>9/22 (40.9%)</td>
<td>0.34\textsuperscript{c}</td>
</tr>
<tr>
<td>Breast pain</td>
<td>10/22 (45.5%)</td>
<td>8/22 (36.3%)</td>
<td>0.37\textsuperscript{c}</td>
</tr>
<tr>
<td>Madden’s mastectomy</td>
<td>17/22 (77.2%)</td>
<td>17/22 (77.2%)</td>
<td>-</td>
</tr>
</tbody>
</table>

QT, chemotherapy; BMI, body mass index.

\textsuperscript{a} Mean ± standard deviation.

\textsuperscript{b} Chi-square test.

\textsuperscript{c} Yates’ correction and Fisher’s exact test.

---

### Table 2: Occurrence and intensity of pain at three different times and postoperative opioid requirement in 24 h.

<table>
<thead>
<tr>
<th></th>
<th>Lidocaine</th>
<th>Placebo</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>Postoperative pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upon awakening</td>
<td>4/22</td>
<td>18.1</td>
<td>5/22</td>
</tr>
<tr>
<td>1st hour of PO (PACU)</td>
<td>14/22</td>
<td>63.6</td>
<td>12/22</td>
</tr>
<tr>
<td>24th hour of PO</td>
<td>11/22</td>
<td>50.0</td>
<td>12/22</td>
</tr>
<tr>
<td>Pain in a 24-h period</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild to moderate</td>
<td>20/22</td>
<td>90.9</td>
<td>19/22</td>
</tr>
<tr>
<td>Severe to very severe 24h</td>
<td>2/22</td>
<td>9.09</td>
<td>3/22</td>
</tr>
<tr>
<td>Postoperative opioid use</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioid 24 h</td>
<td>3/22</td>
<td>13.6</td>
<td>2/22</td>
</tr>
</tbody>
</table>

n, sample; Opioid 24 h, opioid requirement in the first 24 h after surgery; PACU, post-anesthesia care unit; PO, postoperative.
properly to the infusion regimen used, as the pain resulting from cholecystectomies has visceral origin, while the post-mastectomy pain has somatic origin. On the other hand, it should be considered that the severity of pain in the postoperative period of this surgery varies from mild to moderate and the use of simple analgesics such as dipyrone associated with anti-inflammatory drugs results in adequate analgesia.

In this study, opioid requirement was equal in both groups. These data are similar to those reported by other authors who evaluated opioid consumption in women undergoing mastectomy. This result differs from studies with outpatients undergoing laparoscopic surgery, laparoscopic colecotmy, and cholecystectomies, in which the authors observed a decrease of about 50% in opioid consumption during the first 24 h.

A human study shows that there is an excitatory action of the local anesthetic in the intestine smooth muscle and thus a decreased colonic distension and postoperative discomfort. This action justifies the lidocaine ability to alleviate visceral pain, as demonstrated in animal models and proven from the reported results in abdominal surgery.

This positive analgesic response in abdominal surgery can probably be explained by the inhibitory action of intravenous lidocaine in visceromotor reflexes secondary to colon and rectum distention, which contributes to the relief of visceral pain. It is noteworthy that in the pain caused by hip arthroplasty and mastectomy, intravenous lidocaine did not promote analgesia, probably because these surgical procedures result in somatic pain that is less inhibited by lidocaine.

This finding helps to emphasize the hypothesis that intravenous lidocaine has a preferred analgesic effect on visceral and neuropathic pain. However, recent studies have demonstrated that intravenous lidocaine has analgesic and antinociceptive actions resulting from peripheral blockade of nociceptive impulses involved in nociception and also from its action on potassium channels, calcium channels, and G-protein coupled receptors. It also has anti-inflammatory action, an effect resulting from the lower neutrophil accumulation at the site of injury and reduced release of inflammatory mediators. These actions justify its use in multimodal approach to postoperative analgesia.

Some limitations of this study should be considered. Pain was assessed only at rest. It is known that pain can arise or worsen with limb movement on the operated side, and pain assessment at this point could bring additional information. Pain on movement was not assessed because not moving the operated side member in the first 24 h after the surgical procedure is the Mastology Service protocol. The pain symptom evaluation was performed for a short period after surgery (24 h). However, Grigora et al. found no difference between pain scores when evaluated patients undergoing mastectomy up to the seventh postoperative day.

Regarding persistent postoperative pain after mastectomy, the benefit of lidocaine has been observed. However, this type of pain was not assessed in our study.

Therefore, additional studies are needed to identify the lowest dose able to promote analgesia, “What is the most appropriate regime for infusion?”, and finally, identify the value of lidocaine in the multimodal treatment of acute and chronic postoperative pain. Thus, in this study, intravenous lidocaine at a dose of 3 mg kg administered over a 1 h period perioperatively during mastectomy did not promote additional analgesia compared to placebo within the first 24 h and did not decrease opioid consumption. However, a beneficial effect of intravenous lidocaine in selected patients and/or other therapeutic regimens cannot be ruled out.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

We thank the Cristália Produtos Químicos e Farmacêuticos LTDA for the ethical and careful preparation of drugs for the study (lidocaine and placebo).

References